Targeting GOT1 with Ziprasidone HCl: A Metabolic Strategy Against Pancreatic Ductal Adenocarcinoma

Study Background and Research Question

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, primarily due to late diagnosis and poor responsiveness to existing therapies. The five-year survival rate for PDAC is below 10%, underscoring a pressing need for innovative molecular targets and therapeutic approaches. One emerging hallmark of PDAC is metabolic reprogramming, particularly involving glutamine metabolism as a critical nutrient pathway supporting tumor growth and redox homeostasis. The cytosolic enzyme glutamate-oxaloacetate transaminase 1 (GOT1) catalyzes the conversion of aspartate to oxaloacetate, supporting NADPH production and reactive oxygen species (ROS) balance. Previous studies demonstrated that inhibiting GOT1 selectively impairs PDAC cell proliferation without affecting normal tissues, positioning GOT1 as a promising therapeutic target.

Key Innovation from the Reference Study

The reference study presents a novel finding: Ziprasidone hydrochloride (Ziprasidone HCl), a clinically established second-generation antipsychotic, acts as a non-competitive GOT1 inhibitor. While Ziprasidone HCl is primarily known for its antagonistic activity against dopamine D2/D3 and serotonin 5-HT2A/5-HT1A/5-HT2C receptors, this research demonstrates its unexpected potency in disrupting glutamine metabolism by directly targeting GOT1. This mechanistic insight bridges dopaminergic and serotonergic pathway modulation with cancer metabolism, offering a new direction for atypical antipsychotic research in oncology.

Methods and Experimental Design Insights

The investigators employed a combination of enzymatic assays, cellular models, and in vivo studies to assess the impact of Ziprasidone HCl on GOT1 activity and PDAC cell proliferation. Biochemical analyses confirmed non-competitive inhibition of GOT1, with an IC₅₀ of 5.39 ± 1.13 μM for enzyme inhibition and a dissociation constant (K_d) of 89.30 ± 5.35 μM for GOT1 binding. In vitro, PDAC cell lines (SW1990, BxPC-3) were treated with varying concentrations of Ziprasidone HCl, revealing significant antiproliferative effects (IC₅₀ values of 26.71 ± 1.16 μM for SW1990 and 12.19 ± 0.19 μM for BxPC-3). Apoptosis assays and migration studies further substantiated the compound's cytostatic and cytotoxic activities. In vivo, SW1990-derived xenograft models in mice were treated with Ziprasidone HCl, demonstrating substantial tumor growth suppression and no overt toxicity. Metabolomic profiling and redox state analyses indicated pronounced disruption of glutamine metabolism and increased ROS, directly linking GOT1 inhibition to metabolic vulnerability in PDAC cells. Notably, genetic knockdown of GOT1 markedly reduced the antiproliferative effects of Ziprasidone HCl, confirming the specificity and mechanistic dependence of the observed antitumor activity.

Core Findings and Why They Matter

This study delivers several meaningful advances:

• Mechanistic Clarity: Ziprasidone HCl emerges as a direct, non-competitive inhibitor of GOT1, distinguishing itself from previously reported, less selective GOT1 inhibitors.
• Metabolic Reprogramming: By inhibiting GOT1, Ziprasidone HCl disrupts glutamine-derived anabolic pathways, leading to redox imbalance and impaired proliferation in PDAC cells.
• Translational Relevance: The in vivo efficacy of Ziprasidone HCl in PDAC xenograft models, coupled with a favorable safety profile, underscores its potential as a lead compound for further antitumor drug development targeting metabolic vulnerabilities.
• Target Validation: The reduced efficacy following GOT1 knockdown provides strong evidence for GOT1 as a critical mediator of Ziprasidone HCl's antitumor action (reference study).

These results highlight an important intersection between neuroscience research and cancer metabolism, revealing new opportunities for repurposing well-characterized neuropharmacological agents in oncology contexts.

Comparison with Existing Internal Articles

Several internal analyses have previously explored Ziprasidone HCl’s pharmacological roles and formulation strategies. For instance, "Ziprasidone Hydrochloride: Nanocrystal Strategies and Antitumor Innovation" discusses nanocrystal-enabled bioavailability enhancements, which can support experimental reproducibility in both neuroscience and oncology workflows. Meanwhile, another article centers on Ziprasidone HCl’s dual function as a serotonin and dopamine receptor antagonist and GOT1 inhibitor, contextualizing its redox-disruptive effects in cancer models. By contrast, the present reference study advances the field with direct biochemical and genetic validation of GOT1 as a molecular target in PDAC and provides rigorous in vivo evidence, solidifying the translational promise of this metabolic strategy.

Additionally, research in translational neuropharmacology underscores Ziprasidone HCl’s versatility in dopaminergic signaling research and serotonergic pathway modulation, further bridging neuropharmacology and oncology domains as highlighted by the current study.

Limitations and Transferability

While the study robustly demonstrates GOT1-dependent antitumor effects of Ziprasidone HCl in PDAC, several limitations require consideration. The in vivo experiments were conducted in xenograft mouse models, which, although informative, may not fully recapitulate human tumor complexity or the potential for off-target effects in clinical settings. The pharmacokinetics, optimal dosing regimens, and long-term safety of Ziprasidone HCl for oncologic indications remain to be established. Furthermore, the selectivity of metabolic disruption for tumor versus normal tissues warrants deeper investigation, especially given the compound’s established central nervous system activity.

Transferability of these findings to other tumor types or patient populations is not yet validated; caution should be exercised in extrapolating efficacy beyond PDAC until supported by additional preclinical or clinical research.

Protocol Parameters

• In vitro antiproliferative assays: Typical effective concentrations for Ziprasidone HCl range from 10 μM to 40 μM, as observed for apoptosis induction and migration inhibition in PDAC cell lines (reference study).
• Enzyme inhibition: GOT1 inhibition by Ziprasidone HCl observed at an IC₅₀ of 5.39 ± 1.13 μM.
• Animal models: Oral dosing in mouse xenograft models utilized 100–200 mg/kg to achieve tumor growth suppression, with no significant toxicity reported.
• Formulation considerations: For in vitro studies, dissolve Ziprasidone HCl in DMSO at concentrations ≥22.47 mg/mL; compound is insoluble in water and ethanol according to product information.

Research Support Resources

Researchers interested in exploring metabolic vulnerabilities in PDAC or investigating the intersection of atypical antipsychotic research with cancer metabolism can leverage Ziprasidone Hydrochloride (SKU A5350) as a validated GOT1 inhibitor. Detailed specifications and recommended handling protocols are available from APExBIO. This compound supports workflows in dopaminergic and serotonergic pathway modulation, as well as advanced cancer metabolism assays, enabling both mechanistic and translational research in neuroscience and oncology.